SecBot SecBot

CLYM

Climb Bio, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001768446 Biotech & Drug Discovery
$9.15 −1.03 (−10.16%)
Oct 26 4:00 PM ET · prev $10.19
Market cap
$605.4M
Small cap
Consensus
Buy
95% Buy or better · 21 analysts
Median target
🔒 Subscribers only
Next earnings
Nov 11
in 16 days · EPS est. −$0.19
1 year
+336.0%
from $2.10 · Oct 27
30 days
−22.0%
from $11.74
52-week range
$1.64–17.84
−49% from high · low Dec 2
Avg volume 20D
960.4K
shares / day
Short interest
9.72M
≈16.9% of shares · +14.2%
Days to cover
5.6
at average volume
Insider net
-$2.7M
0 buyers · 2 sellers · 12 mo
New fund stakes
3
Q2 2026 13F · 0 exits
SecBot read BULLISH 7 reports · 90 days
Balance 0 bearish · 4 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 4/7 ·Next Earnings date, Nov 11, 2026
Strongest BULLISH Climb Bio announced additional Phase 1 data for CLYM116/MIL116, an anti-APRIL antibody for IgA nephropathy…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $2.7M.

  • InstitutionsBULLISH

    Q2 2026: 22 added (3 new), 7 trimmed or exited. Largest new: Adage Capital Partners Gp, L.L.C $32.7M, Frontier Capital Management $25.3M.

  • AnalystsBULLISH

    20 of 21 rate it Buy or better.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.211 → −$0.194 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +14.2% to 9.72M shares. 5.6 days to cover, ≈16.9% of shares.

  • TrendDOWNTREND

    31% below its 50-day average.

Who's buying

13F· Q2 2026
3
new positions
0
exits
$78.6M
in new stakes
FundMoveSharesValue
FMR LLCDOUBLED6,790,364$88.5M
UBS Group AGDOUBLED3,404,866$44.4M
ADAGE CAPITAL PARTNERS GP, L.L.C.NEW2,506,000$32.7M
BlackRock, Inc.DOUBLED2,354,872$30.7M
FRONTIER CAPITAL MANAGEMENT CO LLCNEW1,939,019$25.3M
VANGUARD CAPITAL MANAGEMENT LLCADD1,698,654$22.2M
Woodline Partners LPNEW1,582,291$20.6M
CITADEL ADVISORS LLCDOUBLED1,297,972$16.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

21 analysts
Buy 95% rate it Buy or better
Strong Buy10Buy10Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 20, 2026Deutsche Bank
INITIATE
INITIATEBuy
Sep 8, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
Sep 8, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Sep 4, 2026B. Riley Securities
REITERATE
REITERATEBuy
Sep 3, 2026BTIG
MAINTAIN
MAINTAINBuy
Sep 3, 2026Baird
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$2.7M
sold · 2 insiders
DateInsiderTypeValue
Sep 28, 2026
RA CAPITAL MANAGEMENT, L.P.
Director
EXERCISE$30.0K
Sep 28, 2026
RA CAPITAL MANAGEMENT, L.P.
Director
EXERCISE$34.6K
Sep 28, 2026
RA CAPITAL MANAGEMENT, L.P.
Director
EXERCISE$78.9K
Sep 28, 2026
RA CAPITAL MANAGEMENT, L.P.
Director
EXERCISE$51.6K
Sep 15, 2026
Thomas Stephen Basil
Director
SELL$1.4M
Jun 29, 2026
RA CAPITAL MANAGEMENT, L.P.
Director
AWARD70,284 sh
Jun 29, 2026
Brennan Aoife
President and CEO
SELL$407.0K
Jun 29, 2026
Celebi Breanna Maurine
Director
AWARD70,284 sh

Earnings setup

Estimates
Nov 11
reports in 16 days
−$0.19
EPS estimate, this quarter
+8%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.19-$0.23–-$0.16+0.0%$0.00
Next Q-$0.21-$0.25–-$0.16+0.0%$0.00
Current FY-$0.78-$0.85–-$0.70+0.0%$0.00
Next FY-$1.00-$1.15–-$0.76+0.0%$500.0K

Short side

FINRA· Sep 30, 2026
9,718,558
shares short
+14.2%
vs prior settlement
5.6
days to cover
≈16.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 24, 2026 Other
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remi
Oct 23, 2026 SEC
Climb Bio announced additional Phase 1 data for CLYM116/MIL116, an anti-APRIL antibody for IgA nephropathy, at ASN…
8-K — Impact 7/10
Oct 23, 2026 Press
Climb Bio reported additional Phase 1 data for CLYM116/MIL116, an anti-APRIL antibody for IgA nephropathy, at ASN…
Impact 7/10
Sep 28, 2026 Insider
RA CAPITAL MANAGEMENT, L.P. acquired via exercise 10,000 shares
Director @ $3.00 ($30.0K)
Sep 28, 2026 Insider
RA CAPITAL MANAGEMENT, L.P. acquired via exercise 10,000 shares
Director @ $3.46 ($34.6K)
Sep 28, 2026 Insider
RA CAPITAL MANAGEMENT, L.P. acquired via exercise 10,000 shares
Director @ $7.89 ($78.9K)
Sep 22, 2026 SEC
22 institutional buyers accumulated $165.0M in net new Climb Bio positions during Q2 2026, overwhelmingly dominated by…
INST-CLUSTER — Impact 3/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
CLYM Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Oct 24, 2026
Press release
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b…
Oct 23, 2026
FDA
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 12 weeks ~33-day half-life ...
Oct 2, 2026
Press release
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation
Aug 6, 2026
Earnings
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026
Jul 15, 2026
Short interest
Short Interest: CLYM up 35% to 6.9M shares
Settlement 2026-07-15 | Days to cover: 5.05 | ≈12.00% of shares outstanding (est.)

SecBot reports

18 filings · 2 press releases · 4 bullish · 3 bearish · 11 neutral
All CLYM filing & press-release reports (20)